GMNN and breast carcinoma: Our discovery that geminin/nuclear c-Abl are frequently overexpressed in TNBCs, and that geminin-overexpressing tumors are highly sensitive to imatinib in pre-clinical mouse model, justify the use of this combination (geminin/nuclear c-Abl) as a biomarker to stratify TNBC patients who may respond to a treatment regimen including imatinib; a drug not commonly used in breast cancer.